EGFR and lung adenocarcinoma: The discovery of EGFR mutations and ALK-rearrangements were the first molecular alterations in lung adenocarcinoma that confer sensitivity to TKIs in 2004 and 2007 (Figure 3), heralding the initiation of the era of precision medicine for lung [15, 47].